which targeted the SIRPα receptor with which CD47 interacts. Last year, AbbVie also pulled out of a $1.3 billion R&D partnership with I-Mab on lemzoparlimab for MDS and AML, for undisclosed ...

肿瘤细胞利用跨膜蛋白 CD47 作为 “别吃我” 信号来逃避吞噬，CD47 - 信号调节蛋白 α（SIRPα）通路是 TAMs 吞噬作用的主要检查点。靶向 CD47 - SIRPα 相互作用以增强 TAM 介导的肿瘤细胞吞噬作用，在多种肿瘤治疗中具有重要潜力 。研究表明，抗 CD47 抗体可以连接 ...

Rentosertib is designed to treat IPF by targeting Traf2- and NCK-interacting kinase (TNIK), a serine/threonine kinase whose activation plays a crucial role in cellular processes that include signal ...

针对 TAMs 的治疗：一方面，通过抑制 TAM 的招募或耗竭 TAMs 来抑制其促癌功能，如阻断 CCL2/CCR2 或 CXCL12/CXCR4 轴，使用巨噬细胞集落刺激因子（M - CSF）抑制剂等；另一方面，通过激活 SIRPα/CD47 等途径，将 TAMs 重编程为具有抗肿瘤活性的细胞2223。 针对 TANs 的治疗 ...

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...